To begin with, the duration of the disclaimer in the beginning was extended by 10 seconds. A 20-second-long disclaimer, mentioning legal safeguards for transgender from sexual offences, was inserted, ...

A pair of abstracts presented at this year’s 64th American Society of Hematology Annual Meeting and Exposition bear out the significant transfusion-free rate at 3 years following beti-cell ...

Beti-cel gene therapy effectively achieves transfusion independence in transfusion-dependent β-thalassemia patients, consistent with clinical trial outcomes. The therapy was initially authorized in ...

Credit: Getty Images. Beti-cel is an investigational one-time gene therapy that works by adding functional copies of a modified form of the beta-globin gene into a patient’s own hematopoietic stem ...

All four parent studies are complete, and all patients have transitioned to a long-term follow-up study (LTF-303) SOMERVILLE, Mass.--(BUSINESS WIRE)--Updated data from bluebird bio inc.’s (NASDAQ: ...

As of March 9, 2021, 51 of 63 beti-cel-treated patients across age groups and genotypes spanning a broad range of TDT severity have completed two years of follow-up in the parent study and were ...

Paycom's near-term growth outlook is uncertain. The company reported a weak quarter, missing revenue guidance and downgrading its revenue estimates for FY23 and FY24. The majority of Paycom's customer ...